Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that the lead investigator for its Phase 2 melanoma study, Professor John F Thompson, MD, today presented clinical data on PV-10 at the “Perspectives in Melanoma XII” meeting at The Hague, The Netherlands. Professor Thompson’s presentation was entitled “PV-10 …
Go here to see the original:
Provectus Lead Investigator Professor John F. Thompson Presents at "Perspectives in Melanoma XII" Conference (Centre Daily Times)
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.